Navigation Links
Tips from the American Journal of Pathology
Date:5/25/2010

ible spongiform encephalopathy.

Dr. Hoover's group suggests that "cervidized transgenic mice substantially recapitulate the clinical, neuropathologic, and PrPRES tropism and transmission patterns reported in the native cervid species and [that] studies in Tg[CerPrP] mice can provide additional insights into the trafficking, shedding, and lateral transmission of [chronic wasting disease] prions."

Seelig DM, Mason GL, Telling GC, Hoover EA: Pathogenesis of Chronic Wasting Disease in Cervidized Transgenic Mice. Am J Pathol 2010 176: 1785-2797


New Target May Inhibit Metastatic Breast Cancer

Researchers led by Dr. Yves St-Pierre at INRS-Institut Armand-Frappier, Qubec, Canada implicate galectin-7 as a breast cancer differentiation marker. They report their data in the May 2010 issue of The American Journal of Pathology.

Breast cancer is the second-most common type of non-skin cancer and the fifth-most common cause of cancer death world-wide. Breast cancer is 100-times more common in women than in men.

The protein galectin-7, which leads to cell death, is expressed in and plays a metastatic role in various types of cancer. To determine the role of galectin-7 in breast cancer, Demers et al investigated galectin-7 expression and function in breast cancer cells. Galectin-7 was highly expressed in two pre-clinical models of breast cancer, and high galectin-7 expression levels increased the metastatic potential of these tumor cells. In humans, high expression levels of galectin-7 were restricted to high-grade tumors and were associated with metastasis. Taken together, these data implicate galectin-7 as both a breast cancer differentiation marker and a potential therapeutic target for metastatic breast cancer.

Dr. St.-Pierre and colleagues "believe that lower survival rates and increased metastases in mice injected with breast cancer cells overexpressing galectin
'/>"/>

Contact: Angela Colmone, Ph.D.
acolmone@asip.org
301-634-7953
American Journal of Pathology
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. American Chemical Societys Weekly PressPac -- Aug. 8, 2007
2. Understanding hypertension in African Americans proves elusive
3. Tips from the Journals of the American Society for Microbiology
4. American Chemical Societys Weekly PressPac -- Aug. 15, 2007
5. American College of Medical Genetics responds to new FDA labeling decision for warfarin
6. American Chemical Societys Weekly Press Pac
7. Highlights from the September 2007 Journal of the American Dietetic Association
8. American Chemical Societys Weekly Presspac -- Aug. 29, 2007
9. Report: African, Asian, Latin American farm animals face extinction
10. American Chemical Society calls green chemistry bill a smart step
11. Challenges remain in reintroducing American chestnut
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... Report Issued by Small Cap IR. In 2011, Nilson Report,s ... at merchants on the leading payment cards rose to $135.3 ... and prepaid cards reached 6.54 billion.  Eight million credit card ... in 2012, and credit and debit card fraud resulted in ...
(Date:1/22/2015)... 22, 2015   EyeLock, Inc. , a market leader of ... Steve Gerber to the new role of Senior Vice ... leading development of mobile platforms and wearable solutions for EyeLock,s ... innovation in the semiconductor industry to his role at EyeLock, ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... MD Researchers from The Johns Hopkins Medical Institutions ... immunohistochemistry to distinguish hydatidiform moles. The related report ... Analytic Validation of a Multiplex Short Tandem Repeat ... The Journal of Molecular Diagnostics . Molar ...
... of sediment cores indicates that biological and chemical changes occurring ... 200,000 years and likely are the result of human-caused climate ... of Colorado at Boulder. While environmental changes at ... be tightly linked with natural causes of climate change -- ...
... 20 Aware, Inc. (Nasdaq: AWRE ), a leading ... results for its third quarter ended September 30, 2009. ... Officer, said, "Earlier today, we announced an agreement to sell ... new fabless semiconductor company being spun out of Infineon. ...
Cached Biology News:Classifying molar pregnancy 2Arctic lake sediments show warming, unique ecological changes in recent decades 2Arctic lake sediments show warming, unique ecological changes in recent decades 3Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... Oct. 27 /Xinhua-PRNewswire/ -- Recently, China Green,Material ... Intellectual,Property Office for two patents for Industrialized ... and Industrialized Production,Method of Fully Biodegradable Edible ... applications have both obtained acceptance numbers,200810064592 and ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) today ... study,demonstrating that repeat administration with TRU-015 continues ... rheumatoid arthritis,(RA) signs and symptoms based on ... announced positive results following preliminary,analyses from a ...
... Inc. ("Carna"),announced on October 27, 2008, the signing ... ("SUBC"). Under the terms of this,Agreement, SUBC will ... China., With China,s emergence as a strong ... companies have now established,research and production facilities in ...
Cached Biology Technology:Patent Technologies Keep CGMT in a Leading Position in the Industry 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company 2
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
Normal sheep serum collected from healthy normal sheep...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Biology Products: